An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.

The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.

The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.

The invention relates to the use of a H3R inverse agonist for the treatment of shift work disorder.

The invention relates to the use of a H3R inverse agonist for the treatment of shift work disorder.

A particulate, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

The disclosure relates to methods for treating or preventing a sleep disorder by administering a compound of formula (1)(1), or a compound of formula (1A), (1B), (1C), (1D), (1E), or (1F) to an animal in need of such treatment. In certain embodiments, such compounds effectively treat or prevent a sleep disorder in the animal, while producing reduced side effects compared to previously available compounds. ##STR00001##

The invention relates to the use of an antagonist and/or inverse agonist of CB1 receptors, in particular Rimonabant, in the treatment of post-viral fatigue syndrome, and more particularly, for the preparation of medicaments useful for treating fatigue after COVID-19. A method of treating post-viral fatigue syndrome in COVID-19 patients comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an antagonist and/or inverse agonist of CB1 receptors.

The invention relates to the use of an antagonist and/or inverse agonist of CB1 receptors, in particular Rimonabant, in the treatment of post-viral fatigue syndrome, and more particularly, for the preparation of medicaments useful for treating fatigue after COVID-19. A method of treating post-viral fatigue syndrome in COVID-19 patients comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an antagonist and/or inverse agonist of CB1 receptors.